JP2018508183A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508183A5 JP2018508183A5 JP2017534208A JP2017534208A JP2018508183A5 JP 2018508183 A5 JP2018508183 A5 JP 2018508183A5 JP 2017534208 A JP2017534208 A JP 2017534208A JP 2017534208 A JP2017534208 A JP 2017534208A JP 2018508183 A5 JP2018508183 A5 JP 2018508183A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- patient
- postn
- signature genes
- stromal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462096355P | 2014-12-23 | 2014-12-23 | |
| US62/096,355 | 2014-12-23 | ||
| US201562200340P | 2015-08-03 | 2015-08-03 | |
| US62/200,340 | 2015-08-03 | ||
| PCT/US2015/067427 WO2016106340A2 (en) | 2014-12-23 | 2015-12-22 | Compositions and methods for treating and diagnosing chemotherapy-resistant cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018508183A JP2018508183A (ja) | 2018-03-29 |
| JP2018508183A5 true JP2018508183A5 (enExample) | 2019-02-07 |
Family
ID=55275162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017534208A Pending JP2018508183A (ja) | 2014-12-23 | 2015-12-22 | 化学療法耐性癌を治療及び診断する組成物及び方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20170253933A1 (enExample) |
| EP (1) | EP3237639A2 (enExample) |
| JP (1) | JP2018508183A (enExample) |
| KR (1) | KR20170094165A (enExample) |
| CN (1) | CN107109491A (enExample) |
| AU (1) | AU2015369624A1 (enExample) |
| BR (1) | BR112017010788A2 (enExample) |
| CA (1) | CA2968359A1 (enExample) |
| HK (1) | HK1243141A1 (enExample) |
| IL (1) | IL252361A0 (enExample) |
| MX (1) | MX2017006864A (enExample) |
| RU (1) | RU2710735C2 (enExample) |
| SG (1) | SG11201704707PA (enExample) |
| WO (1) | WO2016106340A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3548035A4 (en) | 2016-11-30 | 2020-07-22 | Case Western Reserve University | COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES |
| AU2018215678A1 (en) | 2017-02-06 | 2019-08-22 | Board Of Regents Of The University Of Texas System | Compositions and methods of modulating short-chain dehydrogenase activity |
| US20200325543A1 (en) * | 2017-11-20 | 2020-10-15 | Tolremo Therapeutics Ag | Diagnostic method |
| WO2019103456A2 (ko) * | 2017-11-22 | 2019-05-31 | 울산대학교 산학협력단 | Pmvk를 유효성분으로 포함하는 방사선 저항성 암 진단용 또는 방사선 치료 예후 예측용 바이오마커 조성물 |
| KR102141997B1 (ko) | 2017-11-22 | 2020-08-06 | (주)인핸스드바이오 | Pmvk를 유효성분으로 포함하는 방사선 저항성 암 진단용 또는 방사선 치료 예후 예측용 바이오마커 조성물 |
| TWI841554B (zh) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| WO2019191114A1 (en) | 2018-03-27 | 2019-10-03 | The Trustees Of The University Of Pennsylvania | Modified immune cells having enhanced function and methods for screening for same |
| CA3099547A1 (en) | 2018-05-07 | 2019-11-14 | Reshma Abdulla RANGWALA | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate |
| JP2021529784A (ja) * | 2018-06-27 | 2021-11-04 | メドパクト，インコーポレーテッド | 高レベルのＴＧＦ−β応答シグネチャーを発現しているがん患者を診断及び処置する方法 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| TWI844571B (zh) * | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| WO2020092808A1 (en) * | 2018-10-31 | 2020-05-07 | Regents Of The University Of Minnesota | Methods for predicting a response to bevacizumab or platinum-based chemotherapy or both in patients with ovarian cancer |
| IL321451A (en) | 2018-11-21 | 2025-08-01 | Univ Case Western Reserve | Compositions and methods of modulating short-chain dehydrogenase activity |
| JP2022517563A (ja) * | 2019-01-02 | 2022-03-09 | チョーチアン クラウンマブ バイオテック カンパニー リミテッド | タンパク質キナーゼバイオマーカーと組み合わせた、多標的キナーゼ阻害剤を使用したがんの処置 |
| CN110563830B (zh) * | 2019-09-16 | 2021-01-29 | 中南大学湘雅医院 | Anxa1衍生多肽及其应用 |
| TW202128173A (zh) * | 2019-10-09 | 2021-08-01 | 美商G1治療公司 | 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療 |
| CN110950960B (zh) * | 2019-11-26 | 2021-05-14 | 中国农业大学 | 基于高通量测序和杂合杂交瘤技术的小分子化合物抗体的制备方法 |
| JP2023520286A (ja) * | 2020-02-20 | 2023-05-17 | ヴェルシテック リミテッド | Ｐｄ１ベースワクチン接種組成物およびその方法 |
| MX2022010258A (es) | 2020-02-21 | 2023-01-24 | Univ Case Western Reserve | Composiciones y métodos para tratar la lesión renal. |
| CN111440871A (zh) * | 2020-04-26 | 2020-07-24 | 至本医疗科技（上海）有限公司 | 基因标记物在肺癌预后判断中的应用 |
| RU2738167C1 (ru) * | 2020-06-08 | 2020-12-09 | федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии" Министерства здравоохранения Российской Федерации | Способ определения эффективности химиотерапии препаратами платины при раке яичников III-IV стадии |
| JP2024508856A (ja) * | 2021-03-01 | 2024-02-28 | ジェネンテック， インコーポレイテッド | 卵巣がんの診断方法及び処置方法 |
| CN114230656B (zh) * | 2021-03-24 | 2025-02-25 | 深圳市新靶向生物科技有限公司 | 一种与食道癌驱动基因突变相关的抗原肽组合及其应用 |
| CN113174439B (zh) * | 2021-03-30 | 2022-06-28 | 中国医学科学院肿瘤医院 | 一种基于免疫基因对评分体系在预测非小细胞肺癌患者免疫治疗效果中的应用 |
| KR20230001587A (ko) * | 2021-06-28 | 2023-01-05 | 연세대학교 산학협력단 | 암의 예방 또는 치료용 약학 조성물 |
| CN113876753A (zh) * | 2021-10-20 | 2022-01-04 | 复旦大学附属中山医院 | 重组人半乳糖凝集素1抑制剂的制药用途 |
| KR20240035368A (ko) * | 2022-09-07 | 2024-03-15 | 재단법인 아산사회복지재단 | 고형암 환자의 화학요법 내성 억제용 약학 조성물 및 이의 용도 |
| CN117248022A (zh) * | 2023-10-24 | 2023-12-19 | 郑州大学第一附属医院 | 双硫死亡相关基因及风险模型预测肾上腺皮质癌预后及治疗中的应用 |
| CN119224306A (zh) * | 2024-09-26 | 2024-12-31 | 上海交通大学医学院附属仁济医院 | Gprc5a的新用途 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| CA2066428C (en) | 1989-09-08 | 2000-11-28 | Bert Vogelstein | Structural alterations of the egf receptor gene in human gliomas |
| US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| WO1993024640A2 (en) | 1992-06-04 | 1993-12-09 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
| DK1975181T3 (da) | 1992-10-28 | 2011-06-06 | Genentech Inc | Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| DK0659439T3 (da) | 1993-12-24 | 2002-01-14 | Merck Patent Gmbh | Immunkonjugater |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
| HU216142B (hu) | 1994-07-21 | 1999-04-28 | Akzo Nobel N.V. | Ciklusos keton-peroxidokat tartalmazó kompozíciók, és azok alkalmazása (ko)polimerek módosítására |
| US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| JPH11507535A (ja) | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
| EP0836605B1 (en) | 1995-07-06 | 2002-02-06 | Novartis AG | Pyrrolopyrimidines and processes for the preparation thereof |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| JP3370340B2 (ja) | 1996-04-12 | 2003-01-27 | ワーナー―ランバート・コンパニー | チロシンキナーゼの不可逆的阻害剤 |
| DE69716916T2 (de) | 1996-07-13 | 2003-07-03 | Glaxo Group Ltd., Greenford | Kondensierte heterozyklische verbindungen als protein kinase inhibitoren |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| DE69832970T2 (de) | 1997-04-07 | 2006-08-10 | Genentech, Inc., South San Francisco | Humanisierte antikörper und verfahren zu ihrer herstellung |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| IL132240A0 (en) | 1997-04-07 | 2001-03-19 | Genentech Inc | Anti-vegf antibodies |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| ES2201484T3 (es) | 1997-05-06 | 2004-03-16 | Wyeth Holdings Corporation | Utilizacion de compuestos de quinazolina para el tratamiento de la enfermedad de la poliquistosis renal. |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| NZ503991A (en) | 1997-11-06 | 2001-11-30 | American Cyanamid Co | Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps |
| ES2188254T3 (es) | 1998-11-19 | 2003-06-16 | Warner Lambert Co | N-(4-(3-chloro-4-fluoro-fenilamino)-7-(3-morfolin-4-il-propoxi)-quin azolin-6-il)-acrilamada, un inhibidor irreversible de tirosina quinasas. |
| US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| WO2003086467A1 (en) | 2002-04-08 | 2003-10-23 | Smithkline Beecham Corporation | Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor |
| NZ621449A (en) | 2003-05-30 | 2015-07-31 | Genentech Inc | Treatment with anti-vegf antibodies |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| US20060009360A1 (en) | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
| US20110178154A1 (en) * | 2007-02-06 | 2011-07-21 | Birrer Michael J | gene expression profile that predicts ovarian cancer subject response to chemotherapy |
| WO2009074968A2 (en) * | 2007-12-12 | 2009-06-18 | Ecole Polytechnique Federale De Lausanne (Epfl) | Method for predicting the efficacy of cancer therapy |
| WO2011153345A2 (en) * | 2010-06-03 | 2011-12-08 | Beth Israel Deaconess Medical Center, Inc. | A gene expression profile of brca-ness that correlates with responsiveness to chemotherapy and with outcome in cancer patients |
| EP2652498B1 (en) | 2010-12-16 | 2018-04-18 | F.Hoffmann-La Roche Ag | Diagnosis and treatments relating to th2 inhibition |
| CA2867588A1 (en) * | 2012-03-30 | 2013-10-03 | Genentech, Inc. | Diagnostic methods and compositions for treatment of cancer |
| TW201400810A (zh) * | 2012-06-01 | 2014-01-01 | 大鵬藥品工業股份有限公司 | 對胃癌患者選擇化學療法之方法 |
| CA2886607A1 (en) * | 2012-10-17 | 2014-04-24 | Cedars-Sinai Medical Center | Molecular signatures of ovarian cancer |
| CA2893033A1 (en) * | 2012-12-03 | 2014-06-12 | Almac Diagnostics Limited | Molecular diagnostic test for cancer |
-
2015
- 2015-12-22 HK HK18102602.6A patent/HK1243141A1/zh unknown
- 2015-12-22 WO PCT/US2015/067427 patent/WO2016106340A2/en not_active Ceased
- 2015-12-22 RU RU2017125054A patent/RU2710735C2/ru active
- 2015-12-22 KR KR1020177014690A patent/KR20170094165A/ko not_active Withdrawn
- 2015-12-22 BR BR112017010788A patent/BR112017010788A2/pt not_active Application Discontinuation
- 2015-12-22 JP JP2017534208A patent/JP2018508183A/ja active Pending
- 2015-12-22 CA CA2968359A patent/CA2968359A1/en not_active Abandoned
- 2015-12-22 CN CN201580070095.7A patent/CN107109491A/zh active Pending
- 2015-12-22 EP EP15831106.8A patent/EP3237639A2/en not_active Withdrawn
- 2015-12-22 SG SG11201704707PA patent/SG11201704707PA/en unknown
- 2015-12-22 MX MX2017006864A patent/MX2017006864A/es unknown
- 2015-12-22 AU AU2015369624A patent/AU2015369624A1/en not_active Abandoned
-
2017
- 2017-05-17 US US15/597,789 patent/US20170253933A1/en not_active Abandoned
- 2017-05-18 IL IL252361A patent/IL252361A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017125054A (ru) | Композиции и способы лечения и диагностики резистентного к химиотерапии рака | |
| Singh et al. | TNBC: potential targeting of multiple receptors for a therapeutic breakthrough, nanomedicine, and immunotherapy | |
| Huyghe et al. | Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours? | |
| Røsland et al. | Novel points of attack for targeted cancer therapy | |
| Liu et al. | The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4 | |
| Lote et al. | PD-1 and PD-L1 blockade in gastrointestinal malignancies | |
| Basu et al. | Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer | |
| Gilbert et al. | A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma | |
| Kim et al. | Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study | |
| Petrillo et al. | Biomarkers for precision treatment in gastric cancer | |
| JP2019510785A (ja) | 癌を処置する方法 | |
| Alsaafeen et al. | Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors | |
| Ishii et al. | Dawn of precision medicine on gastric cancer | |
| Duenas-Gonzalez et al. | Emerging drugs for cervical cancer | |
| Gui et al. | Tislelizumab plus nab-paclitaxel and cisplatin as induction immunochemotherapy for organ preservation of locally advanced hypopharyngeal squamous cell carcinoma: a single-arm phase II trial | |
| Yao et al. | It’s high-time to re-evaluate the value of induced-chemotherapy for reinforcing immunotherapy in colorectal cancer | |
| JP2017535548A5 (enExample) | ||
| Li et al. | Preoperative pembrolizumab (anti-PD-1 antibody) combined with chemoradiotherapy for esophageal squamous cell carcinoma: a phase 1/2 trial (PALACE-2) | |
| Hall et al. | Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials | |
| RU2017120388A (ru) | Прогнозирование ответа на антагонист vegf | |
| Gui et al. | Efficacy, safety, and multi-omics analysis of pembrolizumab combined with nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: A single-arm phase 2 study | |
| Qi et al. | The co-inhibitory immune checkpoint proteins B7-H1 (PD-L1) and B7-H4 in high grade glioma: from bench to bedside | |
| Wairagu et al. | Combined therapeutic potential of nuclear receptors with receptor tyrosine kinase inhibitors in lung cancer | |
| US20220313724A1 (en) | Compositions for intratumoral administration and related methods | |
| Kenneth | Advances in systemic therapy in pancreatic cancer |